Natural history and epidemiology of HPV infection and cervical cancer

被引:437
作者
Castellsague, Xavier [1 ]
机构
[1] CIBER ESP, IDIBELL, ICO, Unit Infect & Canc, Sao Paulo, Brazil
关键词
D O I
10.1016/j.ygyno.2008.07.045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical cancer is the most common cancer affecting women in developing countries. It has been estimated to have been responsible for almost 260 000 deaths annually, of which about 80% Occurred in developing Countries. Persistent infection by certain oncogenic HPV types is firmly established as the necessary cause of most premalignant and malignant epithelial lesions of the cervix and of a variable fraction of neoplastic lesions of the Vulva, vagina, anus, penis, and oropharynx. There are more than 100 known HPV genotypes, at least 15 of which can cause cancer of the cervix and other sites. HPV 16 and 18, the two most common oncogenic types, cause approximately 70% of all cervical cancers worldwide. FIPV, especially genotypes 6 and I I, can also cause genital warts. HPV is highly transmissible and it is now considered the most common sexually transmitted infection in most populations. Although most women infected with the virus become negative within 2 years, women with persistent high-risk HPV infections are at greatest risk for developing cervical cancer. Since the identification of HPV as the necessary cause of cervical cancer, HPV-based technology has become the centre of novel primary and secondary cervical cancer prevention strategies by the introduction of HPV testing in screening and of HPV vaccines in preadolescent girls and young women. If implemented widely and wisely the deployment of these protocols has the potential to complete Papanicolaou's goal of cervical cancer eradication by extending the benefits of prevention to the developing populations of the world. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:S4 / S7
页数:4
相关论文
共 21 条
[11]   Against which human papillomavirus types shall we vaccinate and screen?: The international perspective [J].
Muñoz, N ;
Bosch, FX ;
Castellsagué, X ;
Díaz, M ;
De Sanjose, S ;
Hammouda, D ;
Shah, KV ;
Meijer, CJLM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :278-285
[12]   Epidemiologic classification of human papillomavirus types associated with cervical cancer [J].
Muñoz, N ;
Bosch, FX ;
de Sanjosé, S ;
Herrero, R ;
Castellsagué, X ;
Shah, KV ;
Snijders, PJF ;
Meijer, CJLM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :518-527
[13]   Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia [J].
Schlecht, NF ;
Kulaga, S ;
Robitaille, J ;
Ferreira, S ;
Santos, M ;
Miyamura, RA ;
Duarte-Franco, E ;
Rohan, TE ;
Ferenczy, A ;
Villa, LL ;
Franco, EL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (24) :3106-3114
[14]   Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update [J].
Smith, Jennifer S. ;
Lindsay, Lisa ;
Hoots, Brooke ;
Keys, Jessica ;
Franceschi, Silvia ;
Winer, Rachel ;
Clifford, Gary M. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (03) :621-632
[15]   Chlamydia trachomatis and invasive cervical cancer:: A pooled analysis of the IARC multicentric case-control study [J].
Smith, JS ;
Bosetti, C ;
Muñoz, N ;
Herrero, R ;
Bosch, FX ;
Eluf-Neto, J ;
Meuer, CJLM ;
van den Brule, AJC ;
Franceschi, S ;
Peeling, RW .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (03) :431-439
[16]  
Smith JS, 2002, JNCI-J NATL CANCER I, V94, P1604, DOI 10.1093/jnci/94.21.1604
[17]  
Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt
[18]  
12::AID-PATH431&gt
[19]  
3.0.CO
[20]  
2-F